Acute Pancreatitis Market Scope And Analysis

  • Report Code : TIPRE00017674
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 196
Buy Now

Analisi di mercato, quota e statistiche sulla pancreatite acuta entro il 2030

Buy Now

Acute Pancreatitis Market Report Acute Pancreatitis Market Size and Share Acute Pancreatitis Market Scope and Analysis

Acute Pancreatitis Market Report Scope

Report AttributeDetails
Market size in 2022US$ 5,649.77 Million
Market Size by 2030US$ 8,827.37 Million
Global CAGR (2022 - 2030)5.7%
Historical Data2020-2021
Forecast period2023-2030
Segments CoveredBy Offerings
  • Medications
  • Diagnosis
  • Others
By Causes
  • Gallstones
  • Alcoholism
  • Genetic Disorders
  • Infections
  • Others
By End User
  • Hospitals
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
  • Others
Regions and Countries CoveredNorth America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott Laboratories
  • GE HealthCare Technologies Inc
  • Samsung Healthcare
  • Koninklijke Philips NV
  • Baxter International Inc
  • Dynavax Technologies Corp
  • Actim Oy
  • Medtronic Plc
  • Boston Scientific Corp
  • Fresenius Kabi AG
   Buy Now   
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Acute Pancreatitis Market News and Recent Developments

The acute pancreatitis market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the acute pancreatitis market are listed below:

  • Arrivo BioVentures announced that the Food and Drug Administration (FDA) has granted its subsidiary, Panafina Inc., Fast Track designation for its investigational new drug, RABI-767, for the treatment of acute pancreatitis predicted to progress to severe disease. RABI-767 is an investigational small-molecule lipase inhibitor that is administered by endoscopic ultrasound-guided peripancreatic injection. RABI-767 is currently being evaluated in a phase 2a trial in patients predicted to develop severe acute pancreatitis. (Source: Arrivo BioVentures, Press Release, July 2024)
  • CalciMedica Inc. announced that its collaborator, St. Jude Children's Research Hospital (SJCRH), presented data from the initial cohort of the Phase 1/2 CRSPA study of Auxora (zegocractin injectable emulsion) in asparaginase-induced pancreatic toxicity (AIPT) at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition on December 2023, in San Diego, CA. (Source: CalciMedica Inc., Press Release, December 2023)

Acute Pancreatitis Market Report Coverage and Deliverables

The “Acute Pancreatitis Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:

  • Acute pancreatitis market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
  • Acute pancreatitis market trends, as well as market dynamics such as drivers, restraints, and key opportunities
  • Detailed PEST and SWOT analysis
  • Acute pancreatitis market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
  • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the acute pancreatitis market
  • Detailed company profiles